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ttps://doi.org/10.1016/j.ajpath.2018.04.008The genetic deletion of apelin receptor early endogenous ligand (Elabela; ofﬁcial name APELA) pro-
duces a preeclampsia-like phenotype in mice. However, evidence linking ELABELA with human disease
is lacking. Therefore, we measured placental mRNA and circulating ELABELA in human samples.
ELABELA mRNA (measured by RNA sequencing) was unchanged in 82 preeclamptic placentas compared
with 82 matched controls (mean difference, 0.53%; 95% CI, 25.9 to 27.0; PZ 0.78). We measured
circulating ELABELA in 32 women with preterm preeclampsia (delivered at <34 weeks’ gestation) and
32 matched controls sampled at the same gestational age. There was no difference in circulating
ELABELA concentrations in the preeclamptic cohort compared with controls (median, 28.5 pg/mL;
95% CI, 5.3 to 63.2 versus median, 20.5 pg/mL; 95% CI, 9.2 to 58.0, respectively); the median
difference was 8.0 pg/mL (95% CI, 17.7 to 12.1; P Z 0.43). In contrast, soluble FLT1 (a protein
with an established association with preeclampsia) mRNA was increased in placental tissue (mean
difference, 34.9%; 95% CI, 16.6 to 53.1; P Z 0.001), and circulating concentrations were 16.8-fold
higher among the preeclamptic cohort (P < 0.0001). In conclusion, we were able to recapitulate the
association between circulating soluble FLT1 and preeclampsia, but there was no association with
ELABELA. The speculated clinical relevance of observations in the murine model linking ELABELA to
preeclampsia likely are incorrect. (Am J Pathol 2018, 188: 1749e1753; https://doi.org/10.1016/
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characterized by hypertension and can cause fetal growth
restriction and injury to the maternal endothelium and
multiple organs.1,2
It is thought that inadequate remodeling of the maternal
spiral arterioles by the extravillous trophoblast generates
periodic placental malperfusion, leading to oxidative and
endoplasmic reticulum stress.1,3,4 This causes increased
placental release of anti-angiogenic factors such as soluble
fms-like tyrosine kinase-1 (sFLT1)5 and soluble endoglin
(ENG).6,7 This leads to maternal endothelial dysfunction,
which then causes hypertension and systemic organ injury.8stigative Pathology. Published by Elsevier Inc.
Y license (http://creativecommons.org/licenses/by/4.0).
Pritchard et alApelin receptor early endogenous ligand (ELABELA;
also known as ELA, ofﬁcial name is APELA) is a circu-
lating peptide hormone that binds to the G-proteinecoupled
apelin receptor (APLNR).9 It has roles in embryonic stem
cell renewal in mice9 and cardiac formation in zebraﬁsh,10
but in adult humans its expression is restricted to the kid-
neys and the placenta.
Recently, Ho et al11 proposed decreased placental release
of ELABELA as a causal factor in preeclampsia. Deletion of
the murine Elabela gene caused preeclampsia-like symp-
toms with proteinuria, hypertension, and kidney injury
during pregnancy. They proposed that loss of Elabela per-
turbs early placental vascular development, resulting in a
placenta that is perfused inadequately. Ho et al11 showed
that Elabela may have paracrine roles in placental devel-
opment, acting on fetal endothelial cells to facilitate normal
branching angiogenesis and formation of the labyrinth
network, allowing proper placental exchange.
As an additional mechanism, decreased circulating
ELABELA was postulated to contribute to the maternal
systemic injury seen in preeclampsia. Circulating ELA-
BELA may act directly on maternal endothelial cells pro-
moting vasodilation12 and regulating diuresis and ﬂuid
balance.9,13e15 In mice, Elabela protects against acute kid-
ney injury,16 an organ commonly injured in preeclampsia,
and reduces blood pressure in the setting of pulmonary
hypertension.17 In support of this, Ho et al11 showed that
circulating Elabela levels correlated with the severity of
maternal proteinuria and kidney damage in mice. Notably,
administering Elabela to pregnant Elabela null mice from
gestational day 7.5 prevented the increase in maternal blood
pressure observed at gestational day 16 in Elabela-null
mice. This treatment also prevented fetal weight loss and
proteinuria with no adverse effects on the fetus.
Although these studies strongly support the hypothesis
that ELABELA is implicated in preeclampsia, as yet there is
no evidence that ELABELA levels are reduced in human
disease. Of the two postulated mechanisms, there is no
obvious way to conﬁrm that ELABELA is indeed deﬁcient
in early placental development among those destined to
develop preeclampsia. However, it is possible to measure
ELABELA mRNA in the delivered placenta and toTable 1 ELABELA/APLN/APLNR/FLT1 Placental Samples: Clinical Chara
Patient characteristic Pregnancy con
Maternal age at delivery (years), median (IQR) 30.2 (25.6e3
Gestation at delivery (weeks), median (IQR) 40.4 (39.4e4
BMI (kg/m2), median (IQR) 26.3 (23.7e3
Highest SBP before labor (mmHg), median (IQR) 120 (116e1
Highest DBP before labor (mmHg), median (IQR) 75.5 (70e80
Birthweight (g), median (IQR) 3550 (3380e
Smoking, n 10
All women were nulliparous. Cases and controls were perfectly matched for feta
used to compare medians. The McNemar test was used to compare paired nomin
APLN, apelin; APLNR, apelin receptor; BMI, body mass index; DBP, diastolic
interquartile range; SBP, systolic blood pressure; FLT1, Fms-like tyrosine kinase-1
1750determine whether circulating ELABELA is deﬁcient
among patients with preeclampsia. Therefore, we measured
placental ELABELA mRNA and circulating ELABELA in
samples obtained from pregnant women with preeclampsia
and healthy controls.Materials and Methods
The Pregnancy Outcome Prediction study was a prospective
cohort of 4512 nulliparous pregnant women with a viable
singleton pregnancy attending theRosieHospital (Cambridge,
UK) between January 14, 2008, and July 31, 2012. This study
has been described previously in detail.18,19 Preeclampsia was
deﬁned (for all participants in this report) according to the
2013 American College of Obstetricians and Gynecologists
criteria20 (Table 1).
Placental tissue was obtained from women with pre-
eclampsia (n Z 82) and from healthy matched controls
(n Z 82). Controls were matched for laboring status, fetal
sex, cesarean section, smoking, maternal body mass index,
gestational age, and maternal age. All participants provided
written informed consent and ethical approval for the study
was given by the Cambridgeshire 2 Research Ethics Com-
mittee (07/H0308/163).
Plasma samples were obtained from women with preterm
preeclampsia delivering at a tertiary hospital in Melbourne,
Australia, between June 2012 and October 2017. Blood was
obtained from women with preterm preeclampsia (n Z 32)
and healthy pregnancies (n Z 32) who delivered without
complications at full term, and were matched for maternal
age and parity. Ethical approval was obtained from The
Mercy Health Human Research Ethics Committee (R11/34).
Preterm preeclampsia was deﬁned as preeclampsia neces-
sitating delivery at <34 weeks’ gestation for maternal or
fetal indications (Table 2).
Placental villous samples were collected within 30 minutes
of delivery and processed as previously described.19 Total
RNA was extracted using the mirVana miRNA Isolation Kit
(Thermo Fisher Scientiﬁc, Waltham MA) followed by DNase
treatment (DNA-free DNA Removal Kit; Thermo Fisher
Scientiﬁc). Sequencing libraries were prepared from 300 tocteristics
trols (n Z 82) Preeclampsia (n Z 82) P value
2.7) 29.6 (25.9e33.4) 0.545
0.9) 40.1 (38.7e40.8) 0.01
0.0) 26.7 (23.6e31.1) 0.002
30) 140 (129.8e150) <0.0001
) 90.0 (80e98) <0.0001
3759) 3530 (3083e3810) 0.062
11 1
l sex, labor status, and caesarean section. The Wilcoxon rank-sum test was
al data (discordant smoking status, 3 pairs out of 82).
blood pressure; ELABELA, apelin receptor early endogenous ligand; IQR,
.
ajp.amjpathol.org - The American Journal of Pathology
Table 2 ELABELA/sFlt1/Soluble ENG Plasma Samples: Clinical Characteristics
Patient characteristic Pregnancy controls (n Z 32) Preeclampsia (n Z 32) P value
Maternal age at delivery (years), median (IQR) 32.4 (29.2e35.3) 32.7 (29.7e35.6) 0.518
Gestation at delivery (weeks), median (IQR) 39.6 (38.7e40.5) 29.7 (27.8e31.5) <0.0001
Gestation at blood collection (weeks), median (IQR)* 28.4 (26.7e30.4) 29.4 (27.4e30.9) 0.254
BMI (kg/m2), median (IQR)y 25 (22e29) 28.5 (25e34) 0.008
Parity, n (%)
0 15 (46.9) 22 (68.8) 0.208
1 12 (37.5) 7 (21.9)
2 5 (15.6) 3 (9.4)
Highest SBP during admission (mmHg), median (IQR) 125 (120e130) 170 (160e180) <0.0001
Highest DBP during admission (mmHg), median (IQR) 78 (72e82) 100 (91e109) <0.0001
Birthweight (g), median (IQR) 3425 (3158e3668) 1078 (810e1403) <0.0001
The U-test was used to compare medians and the c2 test was used to compare categoric variables.
*Gestation at blood collection was available for 31 of 32 controls.
yBMI data were available for 31 of 32 controls and 25 of 32 preeclamptic patients.
BMI, body mass index; DBP, diastolic blood pressure; ELABELA, apelin receptor early endogenous ligand; ENG, endoglin; IQR, interquartile range; SBP,
systolic blood pressure; sFLT1, soluble fms-like tyrosine kinase-1.
ELABELA Levels in Preeclampsia500 ng of total RNA with the TruSeq Stranded Total RNA
Library PrepKit withRibo-ZeroHuman/Mouse/Rat (Illumina,
San Diego, CA). Libraries were quantiﬁed and sequenced
using Illumina HiSeq2500 and HiSeq4000 instruments. To
analyze the RNA sequencing data we used Bioconductor,
cutadapt, Tophat2, subbread, ENSEMBL and R. Primer se-
quences and poor-quality bases were trimmed using cutadapt
version 1.8.121 and the reads were mapped to the human
genome reference (GRCh38) using a two-pass alignment
protocol with TopHat 22.0.12.22 Uniquely mapped reads were
quantiﬁed with Subread/featureCounts version 1.5.1 (http://
subread.sourceforge.net) using the ENSEMBL version 82
(https://www.ensembl.org) transcriptome deﬁnitions.
Transcript abundance was measured in fragments per million
mapped reads using the Bioconductor package DESeq2
version 3.0 (http://bioconductor.org). The mRNAs encoding
ELABELA, apelin, APLNR, FLT1, and ENG were
examined. The statistical signiﬁcance of the fold-changes
were tested by the Wilcoxon signed-rank test in R version
3.1.1 (https://cran.r-project.org).
The following analytes were measured in plasma: ELA-
BELA (human enzyme immunoassay, manufactured by
Peninsula Laboratories, Inc., cat S1508.0001; supplied by
Resolving Images, Preston, Australia); sFLT1 (DuoSet VEGF
R1/FLT1;R&DSystemsBioscience,Waterloo,Australia), and
soluble ENG (DuoSet Human Endoglin; R&D Systems, Wa-
terloo, NSW, Australia). All assays were performed according
to the manufacturers’ instructions without further validation.
Continuous variables were assessed using the U-test for
unpaired nonparametric data, and the Wilcoxon signed-rank
test for paired nonparametric data. Receiver operated char-
acteristic curves were generated. Independence between
categoric variables was assessed with the c2 test and the
McNemar test for paired nominal data (smoking status).
Statistical analysis was conducted using GraphPad Prism 7
(GraphPad Software, La Jolla, CA) and in R. P < 0.05 was
considered signiﬁcant.The American Journal of Pathology - ajp.amjpathol.orgResults
The levels of mRNA in the placentas of 82 women with
preeclampsia were examined at term and in healthy matched
controls. High-quality RNA (RNA integrity number, 7.0 to
9.5; median, 8.2) was puriﬁed and approximately 100 million
125-base single-end sequencing reads were collected for each
sample. The abundance of the mRNAs of interests was
determined. There were no differences in the placental
mRNAs encoding ELABELA [mean fragments per million in
control and pre-eclampsia, respectively, were as follows:
0.532 (95% CI, 0.417 to 0.648) and 0.567 (95% CI, 0.415 to
0.719;PZ 0.78), apelin, 50.5 (95%CI, 45.1 to 55.8) and 47.8
(95% CI, 42.4 to 53.2; PZ 0.448), nor APLNR, the receptor
for these ligands, 74.5 (95% CI, 69.2 to 79.9) and 77.8 (95%
CI, 73.5 to 82.1; PZ 0.398)] (Figure 1, AeC). In contrast,
FLT1 mRNA levels (sFLT1 is a splice variant of FLT1, the
increase of which is associated consistently with preeclamp-
sia) were 1.87-fold higher in women with preeclampsia
(PZ 0.001) (Figure 1D). ENG mRNA was 1.28-fold higher
(ENG, PZ 0.001, data not shown).
We then measured circulating ELABELA concentrations
among 32 women with early onset preeclampsia (delivered
<34 week’s gestation) and compared these with levels in
plasma samples collected from 32 healthy controls
(Table 2). Although gestational age at delivery was signif-
icantly different between the two groups (39.6 versus 29.7
weeks’ gestation; P < 0.001), gestation at the time of blood
collection was equivalent (28.4 and 29.4 weeks’ gestation).
There were no differences between the controls in maternal
age or parity. Body mass index and blood pressure were
higher in the preeclampsia cohort.
There were no differences in circulating ELABELA
levels in the preeclamptic cohort compared with controls
(preeclamptic cohort: median, 28.5 pg/mL; 95% CI, 5.3 to
63.2 versus controls: median, 20.5 pg/mL; 95% CI, 9.2 to
58.0; median difference, 8.0 pg/mL; 95% CI, -17.7 to 12.1;1751
Figure 1 Placental apelin receptor early endogenous
ligand (ELABELA) mRNA is not changed in preeclampsia.
AeC: ELABELA (A), apelin (APLN; B), and apelin receptor
(APLNR; C) mRNA were not altered signiﬁcantly between
groups. D: Fms-like tyrosine kinase-1 (FLT1) mRNA was
altered signiﬁcantly between groups. In all cases, the
Wilcoxon signed-rank test was used and data are shown
with boxes representing the median  interquartile range
and bars representing the median  5th and 95th centile.
mRNAs were measured in preeclamptic (n Z 82) and
control (n Z 82) placentas. *P < 0.001 versus control.
FPM, fragments per million.
Pritchard et alPZ 0.433) (Figure 2, A and B). In contrast, plasma sFLT1
was 16.8-fold higher in preeclamptic women (P < 0.0001)
(Figure 2C). There was perfect discrimination between the
groups (Figure 2D). Soluble endoglin levels also were
signiﬁcantly higher in the women with preeclampsia
(P Z 0.002; area under the curve, 0.77, not shown).Discussion
The demonstration that pregnant Elabela-null mice devel-
oped preeclampsia-like symptoms led Ho et al11 to propose
a role for reduced placental ELABELA production and























































1752they did not show ELABELA was reduced in human dis-
ease. No evidence of any differences was found in ELA-
BELA placental transcript abundance or circulating protein
levels among cases of preeclampsia, compared with
controls.
In Elabela-/- mice major defects in the placental labyrinth
were evident by embryonic day 10.5 and more signiﬁcantly
at embryonic day 18.5. At this time, placental sFlt1 mRNA
also was increased in the null mice. However, in human
placenta ELABELA mRNA did not differ between patients
with preeclampsia and healthy controls even though sFLT1
mRNA was increased. Furthermore, the mRNAs encoding
other components of the apelin-APLNR signaling axis






Figure 2 Circulating apelin receptor early endogenous
ligand (ELABELA) is not decreased in preeclampsia. A and
B: ELABELA levels were not altered signiﬁcantly between
groups: U-test (A) with the receiver operator curve (B)
producing an area under the curve (AUC) of 0.55. C and D:
In contrast, circulating soluble fms-like tyrosine kinase-1
(sFLT1) levels were signiﬁcantly higher when measured in
the preeclamptic cohort (C), with a receiver operator area
under the curve of 1.0 (D). Data are shown with boxes
representing the median  interquartile range and bars
representing the 5th to 95th percentile. Plasma levels of
proteins detected by human enzyme immunoassay in pre-
eclamptic women (nZ 32) and controls (nZ 32) matched
for gestation at blood sampling. *P < 0.0001 versus
control.
ajp.amjpathol.org - The American Journal of Pathology
ELABELA Levels in Preeclampsiawith preeclampsia. This suggests that gross alterations of this
system are not associated with preeclampsia in the placenta at
gestation when the disease becomes clinically evident,
although the possibility remains that ELABELA deﬁciency
might impair early fetal endothelial and placental develop-
ment. In contrast to our negative ﬁndings with ELABELA,
we observed strong associations between sFLT1 and pre-
eclampsia in women. Hence, the negative ﬁndings in relation
to ELABELA are unlikely to be owing to methodologic ﬂaws
in the assays used or the classiﬁcation of cases. Our ﬁndings
do not support the hypothesis that ELABELA perturbation
plays a major role in preeclampsia in women.
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